Exalenz Bioscience
Meridian Bioscience Fiscal Q3 Revenues Soar 75 Percent on COVID-19-Related Life Sciences Growth
The company said it broadened the scope of its life science products to include COVID-19 reagents used by manufacturers to develop rapid antigen tests.
Meridian Bioscience Posts 14 Percent Revenue Increase in Fiscal Q2, Raises FY2020 Guidance
Increased revenues in the company's life science segment due to demand for its COVID-19-related products drove Meridian's overall growth.
Meridian Bioscience to Buy Exalenz Bioscience for $49M
The agreement will bring Exalenz's BreathID Breath Test Systems, a urea breath test platform for H. pylori detection, into Meridian's portfolio.